v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (81,284) $ (108,296)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation expense 10,686 14,051
Depreciation and amortization 10,941 11,296
Noncash operating lease cost 1,399 1,859
Amortization of discount on short-term investments (2,667) (2,000)
Noncash restructuring and other charges   3,605
Noncash lease impairment expense   5,565
Other 93 153
Changes in operating assets and liabilities    
Accounts receivable 9,590 [1] (1,088)
Inventory and other deferred costs 4,425 (1,934)
Prepaid expenses and other assets 1,139 3,748
Accounts payable (8,924) [2] 5,178
Accrued and other current liabilities (2,401) [2] 742
Contract liabilities (4,116) 5,952
Operating lease liabilities (3,505) 894
Other long-term liabilities 1,200 [2] (10)
Net cash used in operating activities (45,150) (56,258)
Cash flows from investing activities:    
Purchases of available-for-sale debt securities (121,708) (103,945)
Proceeds from maturities of available-for-sale debt securities 88,000 127,955
Purchases of property and equipment (1,603) (10,911)
Proceeds from sales of property and equipment 242  
Net cash (used in) provided by investing activities (35,069) 13,099
Cash flows from financing activities:    
Proceeds from sales of common stock under ATM facility, net of commissions 30,079 3,513
Proceeds from issuance of Tempus Warrants   6,000
Proceeds from exercise of Tempus Warrants 18,438  
Proceeds from sale of common stock under Tempus Investment Agreement 17,745  
Proceeds from sale of common stock under Merck Investment Agreement 50,000  
Payment of costs related to Tempus and Merck Investment Agreements (1,230)  
Proceeds from loans   3,438
Repayments of loans (1,130) (3,264)
Proceeds from issuance of common stock under equity incentive plans 770 1,344
Net cash provided by financing activities 114,672 11,031
Effect of exchange rates on cash, cash equivalents and restricted cash (22) (16)
Net change in cash, cash equivalents and restricted cash 34,431 (32,144)
Cash, cash equivalents and restricted cash, beginning of period 58,774 90,918
Cash, cash equivalents and restricted cash, end of period 93,205 58,774
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:    
Cash and cash equivalents 91,415 56,984
Restricted cash, included in other long-term assets 1,790 1,790
Total cash, cash equivalents and restricted cash 93,205 58,774
Supplemental cash flow information:    
Cash paid for income taxes, net of refunds 38 64
Acquisition of property and equipment included in accounts payable and accrued liabilities 473 104
Tempus Warrants    
Adjustments to reconcile net loss to net cash used in operating activities    
Noncash charges related to liability $ 18,274 $ 4,027
[1] Includes a change in related party receivable of $2.0 million for the year ended December 31, 2024.
[2] Includes a change in related party payable and accruals of $0.7 million for the year ended December 31, 2024.